AstraZeneca's new boss said sales and profits would both fall sharply in 2013 as the drugmaker struggles to turn itself around by investing more in-house and on potential acquisitions.
You are receiving this email because you subscribed to this feed at blogtrottr.com.
No comments:
Post a Comment